Medical skilled requires transition from favipiravir to simpler molnupiravir

A leading well being skilled says Thailand should section out the use of favipiravir, saying molnupiravir is a simpler Covid-19 remedy. Dr Opass Putcharoen, from the Thai Red Cross Emerging Infectious Diseases Clinical Centre, says this shall be essential because the country moves to declaring Covid-19 endemic. He added that the value of molnupiravir produced in India is someplace between 600 and seven-hundred baht per therapy course, compared to 50,000 baht for the molnupiravir version produced by Merck.
According to โซล่าเซลล์ราคาถูก , the Public Health Ministry has previously stated that a course of favipiravir prices round 1,000 baht, whereas a molnupiravir therapy course costs 10,000 baht. Earlier this week, Cabinet gave the go-ahead to ditch a procurement plan for 50,000 doses of molnupiravir, in favour of 17 million favipiravir tablets and 5,166 vials of the antiviral medicine, remdesivir.
Opass points out that whereas favipiravir has been the main therapy of alternative in Thailand, there is no clear data that proves its efficacy. By distinction, a recent study reveals that molnupiravir is 30% efficient at preventing extreme illness in Covid-19 patients. The medic is calling on the federal government to import molnupiravir from India and guarantee all hospitals have adequate supplies, so it can be administered promptly to those who want it.
He goes on to say that certain categories of Covid-19 sufferers are still vulnerable to extreme sickness, even if they’re fully vaccinated. These embrace folks on immunosuppressive medicine, who want entry to efficient treatment. He provides that while new infections are anticipated to drop 2 – 3 weeks after the Songkran holiday, the virus still must be closely monitored..

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top